On June 6, 2023 Polymed Biopharmaceuticals reported it has closed an RMB 15 million series pre-A funding round invested by Zhejiang Sundoc Pharmaceutical Science and Tech Co., Ltd (Press release, Polymed Biopharmaceuticals, JUN 6, 2020, View Source [SID1234630611]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The fund from this round will be used for building up and perfecting Polymed’s PROTAC Platform, based on which several PROTAC projects will be carried out to solve the "undruggable targets" problem, and for advancing differentiable drug candidates into preclinical studies.

Doctor Jason Xiang, the CEO of Polymed, believes that the advancement of pharmaceutical industry heavily depends on the breakthrough in technology innovation. The PROTAC approach can clear out the abnormal proteins that cause cancer or autoimmune disease through the proteasome degradation pathway inside the cells, thus may become one important way to solve the "undruggable target" problem. The successful implementation may lead to a new wave of innovative breakthrough in pharmaceutical industry.

On June 5, 2020 BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, reported that the Company will participate in a fireside chat at the Goldman Sachs 41st Annual Global Healthcare Conference on Wednesday, June 10, 2020 at 8:50 a.m. ET (Press release, BeiGene, JUN 5, 2020, View Source [SID1234560881]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the conference can be accessed from the investors section of BeiGene’s website at View Source or View Source An archived replay will be available for 90 days following the event.

On June 5, 2020 Ryvu Therapeutics (WSE: RVU), a clinical-stage biopharmaceutical company developing novel small molecule therapies that address emerging targets in oncology, reported that it has signed a grant agreement with the National Centre for Research and Development for the development of targeted immuno-oncology therapy (Press release, Ryvu Therapeutics, JUN 5, 2020, View Source [SID1234560877]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This grant provides Ryvu with almost USD 5.6 million of non-dilutive financing to discover, develop and select a clinical candidate targeting cancers which had been considered in the past as largely undruggable using rational approaches. Total net value of the project amounts to over USD 8.9 million and the anticipated project duration is until December 2023.

The aim of the project is development of a novel drug candidate, characterized in Phase I clinical study. The selected candidate should overcome the limitations of current immunotherapies, allowing effective and safe treatment options for patients with aggressive, refractory tumors. As a result of the conducted research, a small molecule immunomodulator of the patient’s response against own cancer cells, serving as a strictly personalized therapy, will be identified.

The project is already in progress and the analysis of publicly available and commercial databases has confirmed that currently most advanced, compounds developed by Ryvu in this project, have the potential to become first-in-class medicines.

"Immuno-oncology has undeniably revolutionized the approach to cancer treatment. Immunotherapies offer a new chance to create an effective therapy for patients with aggressive, treatment-resistant cancers. With the financial support of the National Centre for Research and Development we can continue our research in the immune-oncology area at a full speed," commented Krzysztof Brzozka, PhD, Chief Scientific Officer and Executive VP at Ryvu Therapeutics.

On June 5, 2020 Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in antisense therapeutics, reported that management will present a company overview at the following virtual investor conferences (Press release, Ionis Pharmaceuticals, JUN 5, 2020, View Source [SID1234560876]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

William Blair 40th Annual Growth Stock Conference on Wednesday, June 10, 2020;
Goldman Sachs 41st Annual Global Healthcare Conference on Wednesday, June 10, 2020; and
BMO 2020 Prescriptions for Success Healthcare Conference on Tuesday, June 23, 2020.
The above listed dates are subject to change. Details on presentation times or changes to presentation dates can be found on the Company’s website. Please check www.ionispharma.com for the latest information.

A live webcast of the presentations will be available on the Investors & Media section of the Ionis website. The replays will be available within 48 hours and will be archived for a limited time.

On June 5, 2020 Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, reported that it will participate in the upcoming 41st Annual Goldman Sachs Global Healthcare Conference on Thursday, June 11, 2020 (Press release, Mirati, JUN 5, 2020, View Source [SID1234560875]). Charles M. Baum, M.D., Ph.D., President and Chief Executive Officer at Mirati will represent the Company during the fireside chat at 1:20 p.m. EDT/ 10:20 a.m. PDT.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be webcast and made available through the "Investors" section of the Mirati website at www.mirati.com. Replays will be made available for 90 days following the event.